StockData
Immuron Ltd logo

Immuron Ltd (IMRN) stock

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30
$0.87−0.00 (-0.52%)

Close on Nov 18, 2026Market cap $6.99MP/E –Yield –

Immuron revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2026 it was A$7.71M, up 5.9% from the year before. Over ten years it grew 22.7% a year on average. The highest annual figure on record is A$7.71M in fiscal 2026.

Annual revenue

PeriodPeriod endValueChange
FY2026Jun 30, 2026A$7.71M+5.9%
FY2025Jun 30, 2025A$7.29M+48.6%
FY2024Jun 30, 2024A$4.90M+171.7%
FY2023Jun 30, 2023A$1.80M+135.8%
FY2022Jun 30, 2022A$765.19K+424.9%
FY2021Jun 30, 2021A$145.78K-94.2%
FY2020Jun 30, 2020A$2.52M+5.5%
FY2019Jun 30, 2019A$2.39M+63.9%
FY2018Jun 30, 2018A$1.46M+4.3%
FY2017Jun 30, 2017A$1.40M+39.5%
FY2016Jun 30, 2016A$1.00M–

More Immuron figures

See a number that looks wrong?